Gillespie Deirdre 4
4 · LA JOLLA PHARMACEUTICAL CO · Filed May 28, 2010
Insider Transaction Report
Form 4
Gillespie Deirdre
DirectorPresident & CEO
Transactions
- Award
Series D-1 Convertible Pfd Stock Warrants (right to buy)
2010-05-26+104→ 104 totalExercise: $1000.00From: 2010-05-26Exp: 2013-05-26→ Series D-1 Convertible Preferred Stock (104 underlying) - Award
Common Stock
2010-05-26$0.03/sh+437,649$13,129→ 437,649 total - Award
Series C-1 Convertible Preferred Stock
2010-05-26$1000.00/sh+104$104,000→ 104 totalExercise: $0.01From: 2010-12-03→ Common Stock (6,933,368 underlying) - Award
Series C-2 Convertible Pfd Stock Warrants (right to buy)
2010-05-26+208→ 208 totalExercise: $1000.00From: 2010-05-26Exp: 2013-05-26→ Series C-2 Convertible Preferred Stock (208 underlying)
Footnotes (3)
- [F1]The Series C-1 Convertible Preferred Stock (the "Series C-1 Stock") is initially convertible into shares of common stock of La Jolla Pharmaceutical Company at a price per share of $0.015, but such conversion price will be adjusted for certain events, such as stock splits, stock dividends, reclassifications and recapitalizations, and is subject to full-ratchet anti-dilution protection such that any subsequent issuance of common stock below $0.015 automatically adjusts the conversion price of the Series C-1 Stock to such lower price.
- [F2]The Series C-1 Stock does not have a set expiration date, although the holders of such stock may require the Company to redeem the Series C-1 Stock upon certain events.
- [F3]Upon exercise of these Series C-2 Convertible Preferred Stock Warrants, Dr. Gillespie will receive up to 208 shares of Series C-2 Convertible Preferred Stock and warrants to purchase up to 208 shares of Series D-2 Convertible Preferred Stock.